[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641441":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":48,"centralContacts":53,"locations":59,"responsibleParty":133,"collaborators":135,"id":145,"slug":146,"hasResults":147,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":147,"sex":153,"minAge":154,"maxAge":155,"enrollmentInfo":156,"targetDuration":36,"studyType":159,"phases":160,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":171,"whyStopped":36,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"Moscow Multidisciplinary Clinical Center \"Kommunarka\"","OTHER_GOV",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Inflammatory mediatiors adsorption with CytoSorb","EXPERIMENTAL","Inflammatory mediatiors adsorption with EAA \\\u003C0,6 with CytoSorb",[13],"Device: CytoSorb",{"label":15,"type":16,"description":17,"interventionNames":18},"Inflammatory mediatiors adsorption with Jafron HA 330","ACTIVE_COMPARATOR","Inflammatory mediatiors adsorption with EAA \\\u003C0,6 with Jafron HA 330",[19],"Device: Jafron HA 330",{"label":21,"type":10,"description":22,"interventionNames":23},"Endotoxin haemoadsorption with Toramyxin PMX 20R","Endotoxin haemoadsorption with EAA \\[0.6-0.9\\] with Toramyxin PMX 20R",[24],"Device: Toramyxin PMX 20R",{"label":26,"type":16,"description":27,"interventionNames":28},"Endotoxin haemoadsorption with Efferon LPS","Endotoxin haemoadsorption with EAA \\[0.6-0.9\\] with Efferon LPS",[29],"Device: Efferon LPS",[31,37,41,45],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DEVICE","Efferon LPS","Blood purification with Efferon LPS",[26],null,{"type":32,"name":38,"description":39,"armGroupLabels":40,"otherNames":36},"Toramyxin PMX 20R","Blood purification with Toramyxin PMX 20R",[21],{"type":32,"name":42,"description":43,"armGroupLabels":44,"otherNames":36},"Jafron HA 330","Blood purification with Jafron HA 330",[15],{"type":32,"name":46,"description":43,"armGroupLabels":47,"otherNames":36},"CytoSorb",[9],[49],{"name":50,"affiliation":51,"role":52},"Denis Protsenko, MD, PHD","Moscow Multi-disciplinary Clinical Center \"Kommunarka\"","STUDY_DIRECTOR",[54],{"name":55,"role":56,"phone":57,"phoneExt":36,"email":58},"Aleksandr Burov, PHD","CONTACT","+79854215478","Aleksander.bour@mail.ru",[60,76,86,96,100,110,120],{"facility":61,"status":36,"city":62,"state":36,"zip":36,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Bakulev Scientific Center of Cardiovascular Surgery","Moscow","Russia","RU",{"type":66,"coordinates":67},"Point",[68,69],37.61781,55.75204,{"lat":69,"lon":68},[72],{"name":73,"role":56,"phone":74,"phoneExt":36,"email":75},"Mikhail Yarustovskiy, MD, PHD","+79104194682","mbyar@yandex.ru",{"facility":77,"status":36,"city":62,"state":36,"zip":36,"country":63,"countryCode":64,"cosmosGeoPoint":78,"geoPoint":80,"contacts":81},"City clinical hospital named after S. S. Yudin, Moscow City Health",{"type":66,"coordinates":79},[68,69],{"lat":69,"lon":68},[82],{"name":83,"role":56,"phone":84,"phoneExt":36,"email":85},"Nikolay Krotenko, PHD","+79268664976","npkrotenko@gmail.com",{"facility":87,"status":36,"city":62,"state":36,"zip":36,"country":63,"countryCode":64,"cosmosGeoPoint":88,"geoPoint":90,"contacts":91},"City Clinical Hospital No 52, Moscow, Russia",{"type":66,"coordinates":89},[68,69],{"lat":69,"lon":68},[92],{"name":93,"role":56,"phone":94,"phoneExt":36,"email":95},"Rustam Iskhakov","+79265317813","stamius@yandex.ru",{"facility":51,"status":36,"city":62,"state":36,"zip":36,"country":63,"countryCode":64,"cosmosGeoPoint":97,"geoPoint":99,"contacts":36},{"type":66,"coordinates":98},[68,69],{"lat":69,"lon":68},{"facility":101,"status":36,"city":62,"state":36,"zip":36,"country":63,"countryCode":64,"cosmosGeoPoint":102,"geoPoint":104,"contacts":105},"Petrovsky National Research Centre of Surgery",{"type":66,"coordinates":103},[68,69],{"lat":69,"lon":68},[106],{"name":107,"role":56,"phone":108,"phoneExt":36,"email":109},"Maxim Babaev, MD, PHD","+79160269066","maxbabaev@mail.ru",{"facility":111,"status":36,"city":62,"state":36,"zip":36,"country":63,"countryCode":64,"cosmosGeoPoint":112,"geoPoint":114,"contacts":115},"Sklifosovsky Institute of Emergency Care",{"type":66,"coordinates":113},[68,69],{"lat":69,"lon":68},[116],{"name":117,"role":56,"phone":118,"phoneExt":36,"email":119},"Sergei Rei, PHD","+79166001362","reysi@sklif.mos.ru",{"facility":121,"status":36,"city":122,"state":36,"zip":36,"country":63,"countryCode":64,"cosmosGeoPoint":123,"geoPoint":127,"contacts":128},"National Medical Research Centre for Oncology Rostov-on-Don","Rostov-on-Don",{"type":66,"coordinates":124},[125,126],39.70769,47.21997,{"lat":126,"lon":125},[129],{"name":130,"role":56,"phone":131,"phoneExt":36,"email":132},"Natalia Ushakova, MD, PHD","+79185533155","ndu2000@rambler.ru",{"type":134,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[136,138,139,140,141,143],{"name":101,"class":137},"OTHER",{"name":61,"class":6},{"name":77,"class":137},{"name":111,"class":6},{"name":87,"class":142},"UNKNOWN",{"name":144,"class":6},"Rostov Regional Clinical Hospital","100641441","hemoadsorpion-in-patients-with-septic-shock-efficacy-and-safety-evaluation-100641441",false,"NCT07661303","Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation","Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial","HAdSS","Inclusion Criteria:\n\n* Septic shock according to SEPSIS-3 criteria\n* Age: 18-80 years\n* SOFA ≥9 points\n* Diagnosis of septic shock established \\\u003C12 hours ago\n* Invasive hemodynamic monitoring\n* Norepinephrine dose \\>0.2 mcg\u002Fkg\u002Fmin\n\nExclusion Criteria:\n\n* Absolute neutrophil count less than 500 cells\u002FμL\n* Pregnancy\n* End-stage heart failure (NYHA stage IV)\n* Pulmonary embolism with obstructive shock\n* Ongoing bleeding\n* Atonic coma\n* More than 30 points on the MELD scale, class C on the Child-Pugh scale\n* HIV infection\n* Burns over 10% of the body surface area\n* Patients with oncohematological diseases\n* Patients with a recognized palliative status or the definition of \"metastatic cancer\"\n* RRT using membranes with a high cutoff point and increased adsorption capacity within 72 hours from the initiation of the first hemoadsorption procedure\n* Use of plasma exchange within 72 hours from the initiation of the first hemoadsorption procedure","ALL","18 Years","80 Years",{"count":157,"type":158},76,"ESTIMATED","INTERVENTIONAL",[161],"NA","Hemoadsorpion in Patients With Septic Shock: Efficacy and Safety Evaluation. A Pilot Multicenter Randomized Controlled Trial.\n\nThe goal of this clinical trial is the estimation of the efficacy and safety of hemoadsorption procedures (LPS (Lipopolysaccharide) and inflammatory mediators adsorption) in participants with septic shock.\n\nThe main questions it aims to answer are:\n\nDoes hemoadsorption decrease the severity of MODS (multiple organ disfunction syndrome)?\n\nThe study will include participants aged 18 to 80 years with a verified diagnosis of septic shock according to SEPSIS 3 criteria, diagnosed within 12 hours, and a SOFA (sequential organ failure assessment) score of 9 or more.\n\nIn addition to Standard of Care (SOC), blood purification, including hemoadsorption, will be used. The minimum waiting time after diagnosis of septic shock and initiation of basic therapy before inclusion of the patient in the study therapy is 4 hours.\n\nThe choice of procedure will be based on the EAA (Endotoxin Activity Assay) result:\n\n* for an EAA level of 0.6-0.9, selective lipopolysaccharide (LPS) adsorption with duration from 2 to 10 hours;\n* for an EAA level less than 0.6, inflammatory mediator adsorption with duration from 6 to 12 hours.\n\nThe choice of a specific adsorbers within the LPS and inflammatory mediator adsorption group will be based on randomization.\n\nThe use of LPS adsorption is planned based on randomization: Toramyxin R-20 or Efferon LPS. The use of inflammatory mediator adsorption is planned based on randomization: Jafron (HA 330) or CytoSorb.",[164],"Septic Shock",[166,167,168,169,170],"Septic shock","hemoadsorption","blood purification","MODS","Endotoxemia","NOT_YET_RECRUITING","2026-06-30",{"date":174,"type":175},"2026-07-02","ACTUAL",{"date":177,"type":158},"2026-06-25",{"date":179,"type":158},"2027-12-25",{"name":5,"class":6},7]